SLDB - Solid Biosciences Inc.
| Previous Close | 8.50 |
| Open | 8.73 |
| Bid | 8.87 x 800 |
| Ask | 8.99 x 1000 |
| Day's Range | 8.50 - 9.12 |
| 52 Week Range | 5.97 - 54.84 |
| Volume | 1,060,655 |
| Avg. Volume | 766,809 |
| Market Cap | 317.475M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.33 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.83 |
- PR Newswire•3 days ago
Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
- Zacks•8 days ago
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
- Market Realist•15 days ago
Why Solid Biosciences Stock Nosedived 67.82% Yesterday
Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its
- Motley Fool•16 days ago
What Solid Biosciences' First Failure Means for Sarepta Therapeutics
Here's why a competitor's pain was Sarepta's gain recently.
- Investor's Business Daily•16 days ago
Why This Biotech Stock Cratered 68% On Its Gene Therapy Study
Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.
- Barrons.com•16 days ago
A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy
Sarepta Therapeutics solidified its position as the leader in developing a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial released Thursday.
- Business Wire•16 days ago
SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. complied with federal securities laws.
- Motley Fool•16 days ago
Here's Why Solid Biosciences Plunged Today
The company announced disappointing early results for a muscular dystrophy gene therapy.
- American City Business Journals•16 days ago
Solid Biosciences shares drop 70% on disappointing Duchenne data
Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.
Bloomberg•16 days agoSolid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains
The drugmaker fell 73 percent at the market open in New York while shares of Sarepta gained more than 4 percent. JPMorgan analyst Anupam Rama, who has had an underweight rating on Solid Bio for almost a year, said the study update shows the “worst-case scenario” is playing out for the small-cap company. Solid Bio Chief Executive Officer Ilan Ganot said in a phone interview that “the data do not affect our timeline or the competitive nature of our program.” The company said last month that animal models suggested a patient benefit “in the range of 10% or higher” compared to the minimal results seen this morning.
- MarketWatch•16 days ago
Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug
Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patients with Duchenne muscular dystrophy (DMD) who were treated with the drug showed low levels of microdystrophin protein expression. DMD is caused by mutations in the dystrophin gene -- people with the mutation can't make dystrophin protein, which is usually present in skeletal and cardiac muscles and helps protect them from injury. SGT-001 is a drug that delivers to the body a synthetic form of the dystrophin gene that codes for a replacement protein called microdystrophin. The six patients in Solid Biosciences' early-phase trial showed low levels of microdystrophin even after being treated, something the company believes can be fixed with higher doses of the drug. "We believe that SGT-001 will be a meaningful treatment for patients with DMD and are confident we have the right approach in place to evaluate its potential at higher doses. We have already begun working to expedite the planned dose escalation strategy outlined in our clinical trial protocol," said Ilan Ganot, co-founder, CEO and president of Solid Biosciences. Shares of the company have declined 17% in the year to date, while the S&P 500 has gained 9%.
- GlobeNewswire•17 days ago
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Solid Biosciences (SLDB) announced today preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.
- GlobeNewswire•2 months ago
Solid Biosciences to Present at the J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences.
Market Realist•3 months agoSolid Biosciences’ Stock Price Rose 10.5% on November 13
On November 13, Solid Biosciences’ (SLDB) stock price closed at $31.94, which represents ~10.48% growth from the close of $28.91 on November 12. On November 13, Solid Biosciences’ stock price increased after it presented its third-quarter financial results.
- ACCESSWIRE•4 months ago
How This Underfollowed $6 Biotech Could Be Worth $10
The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.
Market Realist•5 months agoSolid Biosciences and Its Focus on Duchenne Muscular Dystrophy
Solid Biosciences (SLDB) is focused on developing products that treat Duchenne muscular dystrophy (or DMD), a genetic muscle-wasting disease caused by mutations in the dystrophin gene. Solid Biosciences’ SGT-001 is being developed to restore functional dystrophin protein expression in patients’ muscles. The drug has received rare pediatric disease designation in the United States and orphan drug designation in the United States and the European Union.
Market Realist•5 months agoWhat Solid Biosciences’ Valuation Trend Indicates
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Market Realist•5 months agoBioMarin Pharmaceutical and Its Promising Research Pipeline
Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).
- Benzinga•6 months ago
Credit Suisse Joins Consensus To Prescribe Sarepta
The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...
